Category: C.R. Bard
Here's a look at some of the top legal news stories for medical device companies this week: Ex-ArthroCare CEO Baker draws 20 years; Smith & Nephew settles whistleblower lawsuit for $8M; Secant Medical escapes pelvic mesh cases; Bellwether trial kicks off for DePuy's Pinnacle hip implant; J&J, Boston Scientific, others can't shake Philly pelvic mesh mass tort
, Boston Scientific
, C.R. Bard
, Dept. of Justice (DOJ)
, DePuy Synthes
, Endo Health
, Ethicon Inc.
, Johnson & Johnson
, Secant Medical
, Smith & Nephew
, U.S. Veterans Affairs Dept. (VA)
, American Medical Systems Holdings Inc.
Johnson & Johnson, Boston Scientific and several other defendants lose their bid for the wholesale dismissal of more than 860 pelvic mesh product liability lawsuits in a Philadelphia court.
ConvaTec is reportedly weighing a sale of the private-equity-owned medical device company next year, even as interest in a Medtronic-like inversion deal mounts from C.R. Bard, CareFusion and 3M.
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany
Here's a look at some of the top Wall Street stories for medical device companies this week: Smith & Nephew CEO reveals new 'no frills' strategy; Bard: We're on track for early 2015 Lutonix approval; Ocular Therapeutix prices IPO below range; Philips' healthcare business suffers in Q2; Intersect ENT prices IPO at low end of range
A recent spate of mega-mergers hasn't inspired medtech peers to follow suit just yet, according to leadership at Boston Scientific, C.R. Bard and Smith & Nephew.
The medical device industry has some blockbuster merger activity in recent months, but a few companies are sitting this one out.
C.R. Bard closes the books on more than 500 patient injury complaints associated with its Avaulta pelvic mesh implants for an undisclosed amount.
C.R. Bard (NYSE:BCR) managed to close the books on a large chunk of patient complaints against its Avaulta mesh implant, settling more than 500 cases in its 2nd quarter.